Phase 1 Mesothelioma Trial, Recruiting NCT06196294 Sponsor: Second Affiliated Hospital of Guangzhou Medical University Condition: Mesothelioma
Back to Mesothelioma

Phase 1 Mesothelioma Trial, Recruiting

NCT06196294
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with advanced cancer that produces a specific protein called GPC3 or Mesothelin.
  • Doctors expect you to live for more than 12 weeks.
  • Your heart, lungs, liver, kidneys, and blood are working well enough to meet the trial's health requirements.
  • A special batch of your own immune cells (called CAR-T cells) has been successfully prepared in the lab and meets the required performance standards for this trial.
  • You (or your legal guardian) have read, understood, and signed a consent form agreeing to take part.

Who may not be able to join:

  • You have previously received gene therapy of any kind.
  • You have a serious viral infection, such as hepatitis B (HBV), hepatitis C (HCV), or HIV.
  • You have tested positive for HIV.
  • You currently have an active infection caused by bacteria, a virus, a fungus, or similar (confirm with trial site).
  • You have another serious illness that the trial doctors feel makes participation unsuitable.
  • You are currently pregnant or breastfeeding.
  • You are taking regular steroid medication at a dose of 0.5 mg or more of prednisone (or an equivalent drug) per kilogram of body weight per day.
  • There are other health or personal reasons that the trial doctors believe make participation unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhenfeng Zhang, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University

Phone: 0086-020-39195965

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
10 May 2024
Est. completion
30 November 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of Patients with Dose Limiting Toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov